INTRODUCTION
Pembrolizumab is a potent, highly selective, humanized IgG4 monoclonal antibody against the immune checkpoint programmed death 1 (PD-1) that has a binding affinity for the PD-1 ligands PD-L1 and PD-L2 in the low nanomolar concentrations (PD-L1 half-maximal inhibitory concentration [IC50], ~0.1 to 0.3 nM and PD-L2 IC50, ~0.5 to 0.9 nM). Consistent with other monoclonal antibodies, pembrolizumab has a low clearance (0.2 L/day), limited central (3.7 L) and peripheral (4.4 L) volume of distribution, and low to moderate variability (22% to 41%) [1] [2] [3] . The half-life is 14-22 days, and serum exposure appears linear over the range of 0.1 to 10 mg/kg at steady-state dosing. Pembrolizumab has demonstrated robust antitumor activity and manageable toxicity across multiple dosages in several advanced malignancies. Pembrolizumab 2 mg/kg every 3 weeks (Q3W) was approved through the US Food and Drug Administration accelerated approval program for previously treated, PD-L1-positive advanced non-small cell lung cancer (NSCLC). A pooled analysis of the first 495 patients with previously treated or treatment-naive advanced NSCLC enrolled in the multicohort phase Ib KEYNOTE-001 study (ClinicalTrials.gov identifier, NCT01295827) demonstrated acceptable toxicity and durable antitumor activity for pembrolizumab, the magnitude of which was dependent on tumor PD-L1 expression [4] .
We present an integrated analysis including efficacy and safety data from the final NSCLC expansion cohort of KEYNOTE-001. This final cohort, which included patients with previously treated NSCLC who received pembrolizumab 2 mg/kg Q3W only, was excluded from the initial publication by Garon et al [4] because it was not part of the planned training or validation sets for PD-L1 expression. We also describe a comprehensive exposure-response model based on tumor size data that was developed using all available NSCLC data from KEYNOTE-001 and employed for pembrolizumab dose selection in advanced NSCLC. This approach has become increasingly common for evaluating growth dynamics and treatment response in oncology [5] [6] [7] and is well suited for integrating and normalizing data from different time points and treatment durations.
METHODS

Study design
KEYNOTE-001 is a multicenter, open-label, phase Ib trial that included multiple advanced NSCLC expansion cohorts. Eligibility criteria for the first 495 patients enrolled were reported previously [4] . Key eligibility criteria for the final cohort included age ≥18 years, locally advanced or metastatic NSCLC, disease progression after platinum-based chemotherapy and an appropriate tyrosine kinase inhibitor for a sensitizing EGFR mutation or ALK translocation if present, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, PD-L1 positivity, adequate organ function, no history of pneumonitis, and no systemic immunosuppressive therapy or active autoimmune disease.
All patients provided written informed consent. The study was conducted in accordance with the protocol, good clinical practice standards, and the Declaration of Helsinki. All protocols and amendments were approved by the appropriate institutional review board or ethics committee at each participating institution.
In the initial KEYNOTE-001 NSCLC cohorts, 489 of 495 patients received pembrolizumab 10 mg/kg Q3W or 10 mg/kg every 2 weeks (Q2W); the final six patients received pembrolizumab 2 mg/kg Q3W before the protocol was amended [4] . Based on data from a randomized comparison in melanoma showing no difference between pembrolizumab 2 and 10 mg/kg Q3W [8] , a final NSCLC cohort was added in which patients received pembrolizumab 2 mg/kg Q3W.
Patients received pembrolizumab until disease progression assessed per immune-related response criteria [9] by investigator review, intolerable toxicity, or investigator or patient decision. Dose delay, prolonged dosing interval, or discontinuation were used to manage toxicity; dose reduction was not allowed. Tumor lesions were measured using computed tomography or magnetic resonance imaging at baseline and every 9 weeks thereafter. Tumor size was recorded as the sum of the longest diameters (SLD) assessed per RECIST v1.1 [10] by independent central review. Adverse events (AEs) were collected throughout the study and for 30 days after treatment discontinuation (90 days for serious AEs) and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. AEs of special interest based on immune etiology ("immune-mediated AEs") were identified from a prespecified list of terms (Table S1 ) and reported regardless of attribution to treatment by the investigator.
PD-L1 expression was assessed in contemporaneous biopsy samples using immunohistochemistry and the 22C3 anti-human PD-1 antibody (Merck) [4] . For enrollment, expression was prospectively assessed using a prototype assay, with positivity defined as membranous staining on ≥1% of cells within tumor nests or staining in stroma. The PD-L1 tumor proportion score (TPS), defined as the percentage of tumor cells with membranous PD-L1 staining, was retrospectively assessed using a clinical trial assay, with positivity defined as TPS ≥1%. Based on the findings by Garon et al [4] , PD-L1 positivity was further categorized as TPS 1% to 49% or ≥50%.
Blood samples (3.5 mL) for peak and trough pharmacokinetic assessment were collected regularly throughout treatment (Supplementary Materials). Regardless of treatment schedule, samples were collected at baseline and week 6. Pembrolizumab serum concentration was assessed using an electrochemiluminescence-based immunoassay with a 10-ng/mL limit of quantitation.
Exposure-Efficacy Analysis
A tiered evaluation approach was employed as part of a comprehensive evaluation, starting with more traditional comparisons of observed efficacy data (exploratory regression analyses) and followed by nonlinear mixed effects (NLME) modeling. Data analysis conducted in a stratified manner for the early analyses was pooled for the NLME model of change from baseline in tumor size because the model's statistical framework was better suited for integrating data.
All patients who had pharmacokinetic data and measurable disease per RECIST v1.1 by central review at baseline were included in the exposure-efficacy regression and NLME modeling analyses (n = 496: n = 6 treatment-naive and 47 previously treated patients received 2 Q3W, n = 45 treatment-naive and 216 previously treated received 10 Q3W, and n = 39 treatment-naive and 143 previously treated received 10 Q2W). Exposure was defined as the area under the concentration-time curve at steady state over 6 weeks (AUCss-6weeks), derived from an independent population pharmacokinetic model (manuscript submitted for publication). AUCss6weeks was chosen as the exposure metric because it provided an integer number of dosing intervals across Q2W and Q3W regimens; steady state was selected for convenience and because pembrolizumab exhibits linear pharmacokinetics. A common steady-state exposure metric was used to avoid potential confounding between early study drop-out unrelated to dose/pharmacokinetic variability and cumulative exposure (ie, patients who progressed early and discontinued treatment ultimately had lower total exposure to pembrolizumab than those treated for a longer duration). Such a correlation could artificially manifest as a positive exposureresponse relationship if a time-dependent exposure metric was chosen. Moreover, because pembrolizumab exhibits linear and time-independent pharmacokinetic behavior, AUCss-6weeks was expected to be a reasonable proxy exposure for all patients (eg, those who had lower AUCss-6weeks are expected to have proportionally lower AUC0-anytime earlier during treatment).
Efficacy was defined as change from baseline in the SLD of target lesions (ie, tumor size).
Change in tumor size was considered an appropriate efficacy measure given the demonstrated relationship between changes in tumor size and overall survival in NSCLC [5, 11, 12] . Before NLME modeling, an exploratory regression analysis was performed to evaluate observed change in SLD versus pembrolizumab exposure at a single post-baseline time point. Particular emphasis was placed on weeks 18 and 27 because at the time of analysis, these were the latest common imaging time points reached by the majority of patients remaining on study who were treated at 2 mg/kg and 10 mg/kg.
Tumor size NLME model structure
All tumor size data were used simultaneously to fit the NLME model. At 2 mg/kg, the majority of data were up to 18 weeks of follow-up, although six patients were observed for >1 year; together with the 10-mg/kg dose groups, these data were used to inform long-term model behavior. Figure S1 and is described mathematically as where "Baseline" is the actual measured tumor size (SLD) at initial screening, kgrowth is the firstorder tumor growth rate, kdeath is the rate constant that captures the kinetics of net removal in the responding portion of the tumor, and "delay" is the delay between baseline and the first dose.
The tumor size model is illustrated in
Both kgrowth and kdeath were constrained to be positive during estimation, with individual parameters log normally distributed.
A fraction (f) of total tumor diameter was assumed to be accessible to treatment, with the remaining portion (1-f) undergoing exponential growth. This model parameterization is similar to previous models in the literature and was sufficiently flexible to capture different patterns of tumor growth observed for NSCLC, as well as for many other solid tumors in pembrolizumabtreated patients.
To account for the effect of drug exposure, AUCss-6weeks was incorporated into the structural model parameterization on the tumor kill rate by assuming a log-linear relationship:
Results from the independent population pharmacokinetics model provided post hoc clearance (CL) estimates, with plasma exposure within the dosing interval at steady state calculated as dose/CL. Here, TVkdeath denotes the typical value of kdeath in the population; "AUCtypical,ss-6weeks" (7079 mg/L × day) is used to normalize exposure values. The estimated value of θ determines the extent of the pembrolizumab exposure-response in NSCLC. Only observed tumor sizes were used for the modeling, with no imputations for missing data.
The patient-specific factors of PD-L1 expression level, smoking history, ECOG performance status, demographics (age, sex, and weight), baseline tumor size, prior treatment, and EGFR mutation status were tested for inclusion in the model using the stepwise covariate modeling function of PsN [13] (forward inclusion at P < 0.01 and backward exclusion at P < 0.001). The Supplementary Methods, including Figures S1-S4 and Tables S2-S6, provide further details on the handling of covariates.
Trial simulations
Response rate simulations were conducted to normalize for potential data imbalances with respect to covariates and dose/exposure. The expected dose-response relationships based on the advanced NSCLC population ( Table S7) . As of the January 23, 2015, data cutoff date, all patients had a minimum follow-up duration of 27 weeks; 15 (27%) patients remained on pembrolizumab. The most common reason for discontinuation was disease progression (n = 20; 36%).
The overall response (ORR) and disease control (DCR) rates per RECIST v1.1 by central review were 15% and 50%, respectively, in patients with measurable disease at baseline (n = 52) ( Table   1 ). ORR was 30% in patients with PD-L1 TPS ≥50% (n = 23), 0% in patients with TPS 1% to 49% (n = 23), and 25% in patients with TPS <1% (n = 4). Decreases from baseline in tumor size were observed for 67% of patients with known PD-L1 expression treated at 2 mg/kg (Figure 1 ).
Among patients treated at 10 mg/kg in randomized cohorts with similar inclusion criteria as the 2-mg/kg cohort, including the amount of prior therapy and requirement for PD-L1 positivity per the prototype assay at baseline, decreases from baseline were observed in 66% of patients treated at Q3W and 63% treated at Q2W (Figure 1) ; ORR and DCR were similar to those of patients treated with pembrolizumab 2 mg/kg ( Table 1) .
Treatment-related AEs were reported for 26 (47%) patients treated with pembrolizumab 2 mg/kg Q3W. Five (9%) patients reported grade 3-5 treatment-related AEs (n = 2 grade 3 colitis, n = 1 grade 5 cardiorespiratory arrest, n = 1 grade 4 pneumonitis, and n = 1 grade 3 pneumonitis). The treatment-related death occurred in a 75-year-old man who was hospitalized on day 30 for possible pneumonia; 3 days later, he died from cardiopulmonary arrest considered by the investigator to be possibly related to pembrolizumab. Three (5%) patients discontinued treatment because of drug-related AEs (n = 1 each grade 5 cardiorespiratory arrest, grade 4 pneumonitis, and grade 3 pneumonitis). Immune-mediated AEs occurred in 9 (15%) patients: colitis (n = 2 grade 3, n = 1 grade 1), hypothyroidism (n = 2 grade 2, n = 1 grade 1), pneumonitis (n = 1 grade 3, n = 1 grade 4), and exfoliative dermatitis (n = 1 grade 1). Considering all 550 patients with NSCLC enrolled in KEYNOTE-001, the AE profile observed at 2 mg/kg Q3W was mostly similar to that observed in patients treated at higher dosages ( Table 2) .
Exploratory Regression and Model-Based Analyses of the Exposure-Efficacy Relationship
Observed tumor size data showed a wide range of longitudinal response patterns across the previously treated population. At week 18, 170 previously treated patients had both tumor size and exposure data. Exploratory graphical analysis of observed tumor size and exposure data from these patients showed a flat relationship between exposure and change from baseline in tumor size at 18 weeks, with overlapping CIs observed between subsets defined by binned AUCss-6weeks (Figure 2) . The linear regression slope estimates were not significantly different from zero, with P values greater than the prespecified significance level (>0.05), regardless of whether the data were pooled or stratified by PD-L1 expression ( Figure S5 ).
In agreement with the exploratory graphical and linear regression analyses of the data observed at week 18, individual pembrolizumab exposures (across all patients) also showed no statistically significant influence on the model-estimated tumor shrinkage rate in an NLME analysis of the exposure-response relationship (P = 0.54 based on −2 log-likelihood reduction and χ 2 test). The 95% CIs of the exposure response parameter were found to overlap with zero (point estimate, 0.196; range, −0.0784 to 0.47), consistent with no significant difference from a flat exposureresponse relationship. PD-L1 expression (Figure 3 and Table S5 ) and EGFR mutation (Table S5 ) status were the only factors found that explained a significant portion of interindividual variability in longitudinal tumor size patterns, with the impact of these factors found to be independent of dose. (Full details of structural model selection and analysis of covariate effects are found in the Supplementary Materials.)
Exposure-Response Simulations
Model-simulated median response rates at week 27 for patients with PD-L1 TPS ≥50% were 39% (90% CI 31% to 46%) at 2 mg/kg Q3W, 40% (90% CI 34% to 45%) at 10 mg/kg Q3W and 44% (90% CI 37% to 49%) at 10 mg/kg Q2W ( Figure 3A) . The CIs for patients with PD-L1 TPS 1% to 49% also showed overlap ( Figure 3B ), and the relationship between kdeath and exposure for PD-L1 TPS <1% was similarly flat (data not shown).
Exposure-Safety Relationship
A total of 544 patients were evaluable for the relationship between exposure and safety. Logistic regression analysis identified treatment duration as a significant factor for occurrence of immune-mediated AEs. After inclusion of treatment duration in the model, no significant relationship between pembrolizumab exposure assessed as AUCss-6weeks and immune-mediated AEs was found (P = 0.57) ( Figure S6) . Similarly, pembrolizumab exposure was not significantly correlated with the hazard for the occurrence of immune-mediated AEs in the time-to-event analysis (P = 1.0). Apart from treatment duration, no other investigated covariate was a significant predictor of the probability of experiencing an immune-mediated AE. Based on simulations from the final logistic regression model, even when forcing a relationship with pembrolizumab exposure, the predicted immune-mediated AE incidence at 9 months was similar for 2 mg/kg Q3W (26%), 10 mg/kg Q3W (27%), and 10 mg/kg Q2W (28%).
DISCUSSION
Based on the observed clinical data and comprehensive clinical pharmacology modeling and simulation, the approved 2-mg/kg Q3W dose of pembrolizumab provides clinically significant antitumor activity in NSCLC, with an efficacy and safety profile comparable to those observed with doses of 10 mg/kg Q3W or 10 mg/kg Q2W. Given that no dose-exposure-response dependency for efficacy or safety was identified between the 2-mg/kg and 10-mg/kg doses, the benefit-risk profile at the higher dose levels is not expected to be better than at 2 mg/kg Q3W.
The analysis supporting these conclusions represents the first comprehensive population pharmacokinetic/pharmacodynamics study of a therapy targeting PD-1/PD-L1 signaling. In this analysis, a NLME modeling framework was used to describe the relationship between systemic pembrolizumab exposure and antitumor efficacy in patients with NSCLC. The efficacy profile of the 2-mg/kg Q3W dose is further supported by early translational and biomarker pharmacokinetic/pharmacodynamic results, whereby potential clinical efficacy was predicted by integrating available preclinical pharmacokinetics, PD-1 receptor occupancy and antitumor data from a syngeneic mouse model, early clinical pharmacokinetic data, and human disease properties [14] . Data from the KEYNOTE-010 study of pembrolizumab 2 and 10 mg/kg Q3W versus docetaxel for previously treated NSCLC support the similar efficacy and safety of pembrolizumab 2 and 10 mg/kg Q3W [15] .
The demonstrated lack of a dose-exposure-response relationship for pembrolizumab raises the question of how to best determine the appropriate dose for immunotherapy. Recently, there has been considerable interest in optimizing dose selection for immunotherapies and other anticancer therapies [16, 17] . Currently, most oncology dose-finding studies are designed to determine the maximum tolerated dose (MTD) based on the rate of prespecified dose-limiting toxicities that occur within a prespecified period of time, usually the first treatment cycle. However, this method may be outmoded for targeted therapies and immunotherapies, for which the biologically effective dose (BED) may be much lower than the MTD [16] . Using the MTD rather than the BED could expose patients to a higher dose than that necessary to achieve clinical effect and may increase toxicity, which could lower overall clinical effectiveness. Therefore, dose determination in oncology should use a multifactorial approach that includes not only clinical data from the first treatment cycle but extended clinical data, preclinical models, pharmacokinetics, pharmacodynamics, and integrated modeling and simulation [16, 17] . Ideally, this multifactorial process would lead to a randomized dose-ranging study appropriately powered to identify the BED.
In summary, the approach reported here provides an integrated framework for exposure-efficacy analysis that accounts for imbalances in data and effects of explanatory covariates more thoroughly than those that rely exclusively on categorical end points (eg, Error bars represent the 90% confidence intervals around the estimates. Response was defined as a ≥30% decrease from baseline in SLD, stable disease was defined as a <30% decrease but <20%
increase from baseline in SLD, and progression was defined as a ≥20% increase from baseline in SLD). CI, confidence interval; SLD, sum of the longest diameters. positivity per the prototype assay at baseline.
b Includes patients for whom a PD-L1 TPS could not be assigned (n = 2 for 2 mg/kg and n = 90 for 10 mg/kg). 
